Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study to Evaluate Safety of Ruxolitinib in Combination With Azacitidine + Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT03874052 is registered in ClinicalTrials.gov with Jennifer Saultz as lead sponsor.

NCT NCT03874052
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03874052 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study to Evaluate Safety of Ruxolitinib in Combination With Azacitidine + Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Lead sponsor
Jennifer Saultz
Phase
Phase 1
Overall status
Recruiting
Start date
August 16, 2019
Completion date
December 31, 2027
Enrollment
51 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia arising from previous myelodysplastic syndrome, recurrent acute myeloid leukemia, recurrent secondary acute myeloid leukemia, refractory acute myeloid leukemia, refractory secondary acute myeloid leukemia